Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

FVIII Inhibitors can Accurately be Measured in the Presence of Mim8 in Hemophilia A Plasma

William Pickering, Karin Weldingh, Mary Robinson, Caroline Cogswell, Mirella Ezban

Blood (2023) 142 (Supplement 1): 5474.

https://doi.org/10.1182/blood-2023-173128

Published: 2023

Journal Articles

In Hemophilia Α Plasma Treated with Emicizumab, Factor IXa in Activated Prothrombin Complex Concentrates Is the Dominant Contributor to Enhanced Thrombin Generation

Dougald Monroe, PhD, Mirella Ezban, PhD, Maureane Hoffman, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-139586

Published: 2020

Journal Articles

In Hemophilia Α Plasma Treated with Emicizumab, Factor IX Activation By Factor VIIa Drives Thrombin Generation

Dougald Monroe, PhD, Mirella Ezban, PhD, Maureane Hoffman, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-139712

Published: 2020

Journal Articles

Evaluation of a Next-Generation FVIII Mimetic Antibody, Mim8, in Combination with Recombinant FVIIa, FVIII and Activated Prothrombin Complex Concentrate

Laurent Burnier, PhD, Mette B Hermit, PhD, Ida Hilden, Mirella Ezban, PhD, Stine L Kjellev, PhDDVM

Blood (2019) 134 (Supplement_1): 2388.

https://doi.org/10.1182/blood-2019-123340

Published: 2019

Journal Articles

Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis

Junjiang Sun, Baolai Hua, Eric W. Livingston, Sarah Taves, Peter B. Johansen, Maureane Hoffman, Mirella Ezban, Dougald M. Monroe, Ted A. Bateman, Paul E. Monahan

Blood (2017) 129 (15): 2161–2171.

https://doi.org/10.1182/blood-2016-08-734053

Published: 2017

Includes: Supplemental data

Journal Articles

The Effect of Prophylactic Recombinant Factor IX and Glycopegylated Factor IX to Normalize Articular Wound Healing Following Hemarthrosis Examined in Hemophilia B Mice

Junjiang Sun, MD, Eric Livingston, Tom Knudsen, DVM, PhD, Dougald M. Monroe, III, PhD, Mirella Ezban, PhD, Ted Bateman, PhD, Paul E. Monahan, MD

Blood (2015) 126 (23): 549.

https://doi.org/10.1182/blood.V126.23.549.549

Published: 2015

Journal Articles

Recombinant FVIII and FVIIa Added to Flowing Hemophiliac Blood Co-Localize with Platelet Aggregates Adherent to a Collagen Surface, Promoting Local Fibrin Deposition in Wake-like Patterns Around the Aggregates

Eric F. Grabowski, MD ScD, Bohan Liu, BA, Matthew Gerace, BA, Paul E. Grabowski, PhD, Peter Gunnarsson, PhD, Mirella Ezban, PhD

Blood (2015) 126 (23): 3499.

https://doi.org/10.1182/blood.V126.23.3499.3499

Published: 2015

Journal Articles

Pharmacokinetics of Multiple Doses of rFVIIa in Patients with Hemophilia With and Without Inhibitors

Camilla Stenmo, MSc, Ihosvany Fernandez-Bello, BSPharm, Mirella Ezban, PhD, Nora V. Butta, Víctor Jiménez-Yuste, PhD

Blood (2014) 124 (21): 2824.

https://doi.org/10.1182/blood.V124.21.2824.2824

Published: 2014

Journal Articles

A novel B-domain O -glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models

Blood (2013) 121 (11): 2108–2116.

https://doi.org/10.1182/blood-2012-01-407494

Published: 2013

Includes: Supplemental data

Journal Articles

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model

Ida Hilden, Brian Lauritzen, Brit Binow Sørensen, Jes Thorn Clausen, Christina Jespersgaard, Berit Olsen Krogh, Andrew Neil Bowler, Jens Breinholt, Albrecht Gruhler, L. Anders Svensson, Helle Heibroch Petersen, Lars Christian Petersen, Kristoffer W. Balling, Lene Hansen, Mette Brunsgaard Hermit, Thomas Egebjerg, Birgitte Friederichsen, Mirella Ezban, Søren Erik Bjørn

Blood (2012) 119 (24): 5871–5878.

https://doi.org/10.1182/blood-2012-01-401620

Published: 2012

Includes: Supplemental data

Journal Articles

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

Blood (2011) 118 (8): 2333–2341.

https://doi.org/10.1182/blood-2011-02-336172

Published: 2011

Includes: Supplemental data

Journal Articles

Characterizing the Effects of NN1731 and rFVIIa In Severe Hemophilia Patients with a Poor Laboratory Response to In Vivo Dosing of rFVIIa 90 μ g/Kg

Donald F Brophy, Pharm.D., Erika J Martin, MT(ASCP), John Christian Barrett, MD, Jan G Kuhn, RN, Melinda Nolte, RN, Ulla Hedner, MD, PhD, Mirella Ezban, Ph.D.

Blood (2010) 116 (21): 4414.

https://doi.org/10.1182/blood.V116.21.4414.4414

Published: 2010

Journal Articles

Increased Platelet Binding of NN1731, a Factor VIIa Variant with Enhanced Tissue Factor-Independent Activity.

Maureane R. Hoffman, MD, PhD, Egon Persson, PhD, Mirella Ezban, Dougald M. Monroe, III, PhD

Blood (2010) 116 (21): 1133.

https://doi.org/10.1182/blood.V116.21.1133.1133

Published: 2010

Journal Articles

Evaluation of Clotting Parameters in a Patient with Hemophilia A and Inhibitors Who Has a Poor Clinical Response to Standard Dose rFVIIa.

Marcus E. Carr, Jr., MD, PhD, Erika J Martin, MT(ASCP), John Christian Barrett, MD, Mindy Nolte, RN, Janice Kuhn, RN, Mirella Ezban, PhD, Ulla Hedner, MD, PhD, Donald Brophy

Blood (2009) 114 (22): 4440.

https://doi.org/10.1182/blood.V114.22.4440.4440

Published: 2009

Journal Articles

Differences in Global Hemostasis Following rFVIIa Dosing: A Focus On Responders Versus Poor Responders.

Donald Brophy, Erika Martin, MT, (ASCP), John Christian Barrett, MD, Mindy Nolte, RN, Janice Kuhn, RN, Marcus E. Carr, Jr., MD, PhD, Mirella Ezban, PhD, Ulla Hedner, MD, PhD

Blood (2009) 114 (22): 3485.

https://doi.org/10.1182/blood.V114.22.3485.3485

Published: 2009

Journal Articles

Formation of FVIIa-Antithrombin Complexes After Administration of rFVIIa to Hemophilia Patients.

Mirella Ezban, PhD, Erika Martin, MT, (ASCP), John Christian Barrett, MD, Janice Kuhn, RN, Mindy Nolte, Hermann Pelzer, Henrik Agerso, Lars Christian Petersen, Ulla Hedner, MD, PhD, Marcus E. Carr, Jr., MD, PhD, Donald Brophy, Pharm.D.

Blood (2009) 114 (22): 1295.

https://doi.org/10.1182/blood.V114.22.1295.1295

Published: 2009

Journal Articles

Successful treatment of canine hemophilia by continuous expression of canine FVIIa

Paris Margaritis, Elise Roy, Majed N. Aljamali, Harre D. Downey, Urs Giger, Shangzhen Zhou, Elizabeth Merricks, Aaron Dillow, Mirella Ezban, Timothy C. Nichols, Katherine A. High

Blood (2009) 113 (16): 3682–3689.

https://doi.org/10.1182/blood-2008-07-168377

Published: 2009

Journal Articles

Effect of glycoPEGylation on Factor VIIa Binding and Internalization

Prosenjit Sen, Ph.D., Samit Ghosh, Ph.D., Pernille K Holm, Ph.D., Mirella Ezban, Ph.D., Usha Pendurthi, Ph.D., L. Vijaya Mohan Rao, Ph.D.

Blood (2008) 112 (11): 1029.

https://doi.org/10.1182/blood.V112.11.1029.1029

Published: 2008

Journal Articles

Acidosis in Human Whole Blood Does Not Necessarily Impair the Coagulation and the Effect of RFVIIa.

Dorthe Viuff, PhD, Marianne Kjalke, PhD, Vivian Lind, Egon Persson, PhD, Mirella Ezban, PhD

Blood (2007) 110 (11): 3930.

https://doi.org/10.1182/blood.V110.11.3930.3930

Published: 2007

Journal Articles

Activity and Regulation of Long-Acting Factor VIIa Analogs.

Samit Ghosh, PhD, Prosenjit Sen, Ph.D, Mirella Ezban, Ph.D., Usha R. Pendurthi, Ph.D., L. Vijaya Mohan Rao

Blood (2007) 110 (11): 3141.

https://doi.org/10.1182/blood.V110.11.3141.3141

Published: 2007

NARROW

FVIII Inhibitors can Accurately be Measured in the Presence of Mim8 in Hemophilia A Plasma

In Hemophilia Α Plasma Treated with Emicizumab, Factor IXa in Activated Prothrombin Complex Concentrates Is the Dominant Contributor to Enhanced Thrombin Generation

In Hemophilia Α Plasma Treated with Emicizumab, Factor IX Activation By Factor VIIa Drives Thrombin Generation

Evaluation of a Next-Generation FVIII Mimetic Antibody, Mim8, in Combination with Recombinant FVIIa, FVIII and Activated Prothrombin Complex Concentrate

Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis

The Effect of Prophylactic Recombinant Factor IX and Glycopegylated Factor IX to Normalize Articular Wound Healing Following Hemarthrosis Examined in Hemophilia B Mice

Recombinant FVIII and FVIIa Added to Flowing Hemophiliac Blood Co-Localize with Platelet Aggregates Adherent to a Collagen Surface, Promoting Local Fibrin Deposition in Wake-like Patterns Around the Aggregates

Pharmacokinetics of Multiple Doses of rFVIIa in Patients with Hemophilia With and Without Inhibitors

A novel B-domain O -glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

Characterizing the Effects of NN1731 and rFVIIa In Severe Hemophilia Patients with a Poor Laboratory Response to In Vivo Dosing of rFVIIa 90 μ g/Kg

Increased Platelet Binding of NN1731, a Factor VIIa Variant with Enhanced Tissue Factor-Independent Activity.

Evaluation of Clotting Parameters in a Patient with Hemophilia A and Inhibitors Who Has a Poor Clinical Response to Standard Dose rFVIIa.

Differences in Global Hemostasis Following rFVIIa Dosing: A Focus On Responders Versus Poor Responders.

Formation of FVIIa-Antithrombin Complexes After Administration of rFVIIa to Hemophilia Patients.

Successful treatment of canine hemophilia by continuous expression of canine FVIIa

Effect of glycoPEGylation on Factor VIIa Binding and Internalization

Acidosis in Human Whole Blood Does Not Necessarily Impair the Coagulation and the Effect of RFVIIa.

Activity and Regulation of Long-Acting Factor VIIa Analogs.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only